Abbott Laboratories – SWOT Framework Analysis
Being an internationally famous pharmaceutical brand, Abbott Laboratories has some of the most famous drugs in its portfolio. Some of the most popular ones include:
The company’s latest financials include:
Taking a look at the global pharmaceutical industry, sales of prescription and over-the-counter (OTC) drugs are worth over $600 billion yearly. The US leads the world in this industry, claiming both the largest market share and five of the ten largest companies (Bristol-Myers Squibb, Johnson & Johnson, Merck & Co., Pfizer, and Abbott Laboratories). Europe takes second place, even as the industry comes under more regulatory pressure here. Japan brings in the third place, as its super-regulated pharma industry comes out from the economic turmoil that has plagued the region.
It is a fact that pharma companies are having a tougher time in mature markets such as North America and Western Europe, whereas emerging markets such as China, India, Turkey, etc., are proving to be very promising for industry players.
It is in this industry scenario that Aruvian’s places Abbott Laboratories and carries out a SWOT analysis of the company – giving an idea about what edge the company posses over its competitors such as Merck, Novartis, etc.
Aruvian’s R’search analyzes the company Abbott Laboratories in the SWOT Framework Analysis. The report includes the following:
- Humira: a drug for rheumatoid arthritis, psoriatic arthritis, Crohn's disease, and moderate to severe chronic psoriasis;
- Norvir: a treatment for HIV
- Depakote: an anticonvulsant drug
- Synthroid: a synthetic thyroid hormone.
The company’s latest financials include:
- Revenues of $30,764.7 million during FY 2009 - primary reason for growth being the increased sales of Humira and Lupron.
- Operating Profit of $6,235.7 million during FY2009
- Net profit of $5,745.8 million in FY2009
- Strengths
- Weaknesses
- Opportunities
- Threats
Taking a look at the global pharmaceutical industry, sales of prescription and over-the-counter (OTC) drugs are worth over $600 billion yearly. The US leads the world in this industry, claiming both the largest market share and five of the ten largest companies (Bristol-Myers Squibb, Johnson & Johnson, Merck & Co., Pfizer, and Abbott Laboratories). Europe takes second place, even as the industry comes under more regulatory pressure here. Japan brings in the third place, as its super-regulated pharma industry comes out from the economic turmoil that has plagued the region.
It is a fact that pharma companies are having a tougher time in mature markets such as North America and Western Europe, whereas emerging markets such as China, India, Turkey, etc., are proving to be very promising for industry players.
It is in this industry scenario that Aruvian’s places Abbott Laboratories and carries out a SWOT analysis of the company – giving an idea about what edge the company posses over its competitors such as Merck, Novartis, etc.
Aruvian’s R’search analyzes the company Abbott Laboratories in the SWOT Framework Analysis. The report includes the following:
- Business segment analysis of Abbott Laboratories
- Major products & services of Abbott Laboratories
- Profile of the industry Abbott Laboratories operates in,
- Profile of its major competitors – Johnson & Johnson, Merck & Co., Inc., Novartis AG and the Sanofi-Aventis Group
- SWOT Analysis of Abbott Laboratories
- Future Perspective of Abbott Laboratories
A. EXECUTIVE SUMMARY
B. PROFILE OF ABBOTT LABORATORIES
B.1 Industry Profile
B.2 Corporate Profile
B.3 Business Segment Analysis
B.4 Major Products & Services
B.5 Future Perspective: Abbott Laboratories
C. COMPETITOR PROFILES
C.1 Johnson & Johnson
C.1.1 Corporate Profile
C.1.2 Business Segment Analysis
C.2 Merck & Co., Inc.
C.2.1 Corporate Profile
C.2.2 Business Segment Analysis
C.3 Novartis AG
C.3.1 Corporate Profile
C.3.2 Business Segment Analysis
C.4 Sanofi-Aventis Group
C.4.1 Corporate Profile
C.4.2 Business Segment Analysis
D. SWOT FRAMEWORK ANALYSIS
D.1 Strengths to Build Upon
D.2 Weaknesses to Overcome
D.3 Opportunities to Exploit
D.4 Threats to Overcome
E. GLOSSARY OF TERMS
B. PROFILE OF ABBOTT LABORATORIES
B.1 Industry Profile
B.2 Corporate Profile
B.3 Business Segment Analysis
B.4 Major Products & Services
B.5 Future Perspective: Abbott Laboratories
C. COMPETITOR PROFILES
C.1 Johnson & Johnson
C.1.1 Corporate Profile
C.1.2 Business Segment Analysis
C.2 Merck & Co., Inc.
C.2.1 Corporate Profile
C.2.2 Business Segment Analysis
C.3 Novartis AG
C.3.1 Corporate Profile
C.3.2 Business Segment Analysis
C.4 Sanofi-Aventis Group
C.4.1 Corporate Profile
C.4.2 Business Segment Analysis
D. SWOT FRAMEWORK ANALYSIS
D.1 Strengths to Build Upon
D.2 Weaknesses to Overcome
D.3 Opportunities to Exploit
D.4 Threats to Overcome
E. GLOSSARY OF TERMS